MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers

• Published in: Diagnostic pathology Vol. 17; no. 1; p. 24
• Main Authors: Sadeghian, Dorsay, Saffar, Hana, Mahdavi Sharif, Pouya, Soleimani, Vahid, Jahanbin, Behnaz
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.02.2022; BioMed Central; BMC
• Subjects: Analysis; Biomarkers; Biomarkers, Tumor - metabolism; Brain cancer; Breast cancer; Breast Neoplasms - genetics; Cancer therapies; Cell cycle; Cloning; Cross-Sectional Studies; Epidermal growth factor; ErbB-2 protein; Female; Growth factors; Humans; Information retrieval; Ki-67 Antigen - metabolism; Ki67; Luminal a; Luminal B; MCM6; Medical prognosis; Minichromosome Maintenance Complex Component 6; Monoclonal antibodies; Pleomorphism; Prognosis; Proteins; Receptor, ErbB-2 - metabolism; Receptors; Receptors, Progesterone - metabolism; Retrospective Studies; Statistical analysis; Subgroups; Survival analysis; Tumors; Biomarkers; Diagnostic; Breast cancer; MCM6; Ki67; Luminal B; Luminal a

Currently, breast cancers are divided into four major molecular subtypes. The distinction between the luminal A and luminal B subtypes is mainly based on the cellular proliferation indices and is assessed by the Ki-67 scoring. Due to the limitations in the assessment and expression of Ki-67, we hypo...